VAXART INC WKN: A2JD8X ISIN: US92243A2006 Kürzel: VXRT Forum: Aktien Thema: Hauptdiskussion

Keine Panik auf Titanik

Von 12.50auf unter 9😵

Puhhh

Ich weiss nicht was waren die Analystenerwartungen

Wenn man q1 2020 und 2021 vergleicht, natürlich sind mehr Verluste drin

Vaxart ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3 million, compared to $126.9 million as of December 31, 2020. The increase was primarily due to receipts of $65.7 million from the Company’s $250 million at-the-market facility entered into in October 2020 and $1.9 million from the exercise of warrants and options, partially offset by $16.6 million of cash used in operations and $0.6 million spent on property and equipment. Financial Results for the Three Months Ended March 31, 2021: Vaxart reported a net loss of $16.0 million for the first quarter of 2021 compared to $1.3 million for the first quarter of 2020. Net loss per share for the first quarter of 2021 was $0.14, compared to a net loss of $0.02 in the first quarter of 2020. The increase in net loss per share was due to the increase in net loss partially offset by the increase in the weighted average number of shares outstanding. Revenue for the first quarter of 2021 was $506,000 compared to $2.9 million in the first quarter of 2020. The decrease was principally due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Research and development expenses were $10.1 million for the first quarter of 2021 compared to $1.5 million for the first quarter of 2020. The increase was mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates. General and administrative expenses were $5.9 million for the first quarter of 2021 compared to $2.0 million for the first quarter of 2020. The increase was mainly due to higher legal and insurance expenses, and an increase in headcount and related costs.

und eben den dip genutzt um nochmal bisschen nachzukaufen :-), hoffentlich geht die Rechnung auf

Sind die news gut oxa? Hab grad leider nicht die zeit mir das genau durchzulesen.

Manno man, Achterbahn 🎢 ist ja gar nichts dagegen 😅👍

Find ich super. Von mir aus gerbe bis 15:30 so haben die Amis dann die besten vorraussetzungen wieder 30%+ zu machen

Next steps Pre-clinical studies: Several studies with our S and N and S-only constructs in multiple animal models are ongoing or will begin soon, testing attributes of our vaccine candidates such as impact on infection, illness, shedding, transmission, and cross-variant protection. Clinical studies: A Phase II trial of VXA-CoV2-1, our vaccine encoding both the S and the N proteins, is expected to start mid-year 2021 instead of 2Q. The delay is due to manufacturing issues at the Baltimore contract manufacturing facility, the same facility where other COVID-19 vaccine manufacturers have also reported issues. Manufacturing of our vaccines is currently underway at the Company’s other manufacturing partner, and at our own GMP facility. We are also evaluating additional manufacturing partners both in the U.S. and abroad. Phase I/II studies of two S-only vaccine constructs targeting different variants are planned to begin in 3Q 2021. Boosting studies with previously vaccinated or infected subjects are also planned for 2H 2021. Trials in India and Latin America are expected to initiate in 2021.

As previously announced, later today Vaxart will provide new data comparing the T-cell responses induced by its VXA-CoV2-1 vaccine with those of other vaccines. The Company will also present new mucosal antibody data and review the recent Phase 1 clinical results that suggest VXA-CoV2-1 is potentially protective against new and future COVID-19 strains due to the vaccine’s more conserved target.

Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update May 3, 2021 at 8:00 AM EDT

LoL😂😂😂 wird sicher wieder wie auch an Freitag aufgekauft

CYDY Be the hero to the world by approving a therapeutic that works!! Approve #leronlimab to save more lives. We’ve lost too many

Nun aber mal Gas geben